Consensus Rating1
Buy
Highest Price Target1
$1200.00
Lowest Price Target1
$547.00
Consensus Price Target1
$920.21

Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga

Regeneron Pharmaceuticals Inc has a consensus price target of $920.21 based on the ratings of 29 analysts. The high is $1200 issued by TD Cowen on July 23, 2024. The low is $547 issued by B of A Securities on April 17, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Citigroup, and Guggenheim on May 27, 2025, May 14, 2025, and May 1, 2025, respectively. With an average price target of $817.67 between RBC Capital, Citigroup, and Guggenheim, there's an implied 36.11% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Feb
1
Mar
12
3
1
Apr
3
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Citigroup
Guggenheim
Truist Securities
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Regeneron Pharmaceuticals

Buy NowGet Alert
05/27/2025Buy Now56.97%RBC Capital
Brian Abrahams49%
$943 → $943ReiteratesOutperform → OutperformGet Alert
05/14/2025Buy Now16.52%Citigroup
Geoff Meacham67%
$600 → $700UpgradeNeutral → BuyGet Alert
05/01/2025Buy Now34.83%Guggenheim
Yatin Suneja58%
$940 → $810MaintainsBuyGet Alert
04/30/2025Buy Now56.47%Truist Securities
Srikripa Devarakonda45%
$975 → $940MaintainsBuyGet Alert
04/30/2025Buy Now33.83%Goldman Sachs
Salveen Richter54%
$917 → $804MaintainsBuyGet Alert
04/30/2025Buy Now56.97%RBC Capital
Brian Abrahams49%
$1051 → $943MaintainsOutperformGet Alert
04/30/2025Buy Now16.52%Wells Fargo
Mohit Bansal68%
$750 → $700MaintainsOverweightGet Alert
04/30/2025Buy Now33.17%BMO Capital
Evan David Seigerman47%
$865 → $800MaintainsOutperformGet Alert
04/30/2025Buy Now5.37%UBS
Trung Huynh66%
$768 → $633MaintainsNeutralGet Alert
04/30/2025Buy Now-2.29%Baird
Brian Skorney59%
$652 → $587MaintainsNeutralGet Alert
04/29/2025Buy Now49.81%Oppenheimer
Hartaj Singh46%
$925 → $900MaintainsOutperformGet Alert
04/25/2025Buy Now8.53%Baird
Brian Skorney59%
$759 → $652MaintainsNeutralGet Alert
04/23/2025Buy Now62.3%Truist Securities
Srikripa Devarakonda45%
$1004 → $975MaintainsBuyGet Alert
04/22/2025Buy Now41.49%Canaccord Genuity
John Newman45%
$1152 → $850MaintainsBuyGet Alert
04/22/2025Buy Now15.69%Cantor Fitzgerald
Carter Gould57%
→ $695Assumes → OverweightGet Alert
04/17/2025Buy Now-8.95%B of A Securities
Tim Anderson58%
$575 → $547MaintainsUnderperformGet Alert
04/14/2025Buy Now52.64%Goldman Sachs
Salveen Richter54%
$1019 → $917MaintainsBuyGet Alert
04/09/2025Buy Now79.94%Morgan Stanley
Matthew Harrison61%
$1150 → $1081MaintainsOverweightGet Alert
04/03/2025Buy Now53.98%Oppenheimer
Hartaj Singh46%
$950 → $925MaintainsOutperformGet Alert
03/31/2025Buy Now66.46%JP Morgan
Chris Schott40%
$1100 → $1000MaintainsOverweightGet Alert
02/05/2025Buy Now26.34%Baird
Brian Skorney59%
$940 → $759MaintainsNeutralGet Alert
02/05/2025Buy Now38.83%Leerink Partners
David Risinger70%
$762 → $834UpgradeMarket Perform → OutperformGet Alert
01/28/2025Buy Now24.84%Citigroup
Geoff Meacham67%
$795 → $750MaintainsNeutralGet Alert
01/27/2025Buy Now68.62%Piper Sandler
Christopher Raymond56%
$1195 → $1013MaintainsOverweightGet Alert
01/16/2025Buy Now22.85%UBS
Trung Huynh66%
$1130 → $738DowngradeBuy → NeutralGet Alert
01/14/2025Buy Now32.34%Citigroup
Geoff Meacham67%
$895 → $795MaintainsNeutralGet Alert
01/10/2025Buy Now58.14%Oppenheimer
Hartaj Singh46%
$1000 → $950MaintainsOutperformGet Alert
01/10/2025Buy Now49.81%Wells Fargo
Mohit Bansal68%
$1050 → $900MaintainsOverweightGet Alert
01/08/2025Buy Now67.13%Truist Securities
Srikripa Devarakonda45%
$1126 → $1004MaintainsBuyGet Alert
01/07/2025Buy Now78.11%Bernstein
William Pickering39%
$1110 → $1070MaintainsOutperformGet Alert
12/10/2024Buy Now-5.95%B of A Securities
Tim Anderson58%
→ $565Reinstates → UnderperformGet Alert
11/15/2024Buy Now91.43%Wolfe Research
Alexandria Hammond45%
→ $1150Initiates → OutperformGet Alert
11/14/2024Buy Now48.98%Citigroup
Geoff Meacham67%
→ $895Initiates → NeutralGet Alert
11/06/2024Buy Now66.46%Oppenheimer
Hartaj Singh46%
$1150 → $1000MaintainsOutperformGet Alert
11/01/2024Buy Now97.09%Morgan Stanley
Matthew Harrison61%
$1235 → $1184MaintainsOverweightGet Alert
11/01/2024Buy Now102.25%RBC Capital
Brian Abrahams49%
$1260 → $1215MaintainsOutperformGet Alert
11/01/2024Buy Now77.28%Barclays
Carter Gould57%
$1080 → $1065MaintainsOverweightGet Alert
11/01/2024Buy Now98.92%Piper Sandler
Christopher Raymond56%
$1242 → $1195MaintainsOverweightGet Alert
11/01/2024Buy Now98.09%BMO Capital
Evan David Seigerman47%
$1300 → $1190MaintainsOutperformGet Alert
11/01/2024Buy Now87.43%Truist Securities
Srikripa Devarakonda45%
$1137 → $1126MaintainsBuyGet Alert
10/25/2024Buy Now109.74%RBC Capital
Brian Abrahams49%
$1260 → $1260ReiteratesOutperform → OutperformGet Alert
10/24/2024Buy Now95.59%Evercore ISI Group
Cory Kasimov66%
$1250 → $1175MaintainsOutperformGet Alert
10/24/2024Buy Now91.43%JP Morgan
Chris Schott40%
$1200 → $1150MaintainsOverweightGet Alert
10/23/2024Buy Now68.96%Cantor Fitzgerald
Olivia Brayer54%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
10/23/2024Buy Now79.78%Barclays
Carter Gould57%
$1220 → $1080MaintainsOverweightGet Alert
10/22/2024Buy Now74.78%Wells Fargo
Mohit Bansal68%
$1200 → $1050MaintainsOverweightGet Alert
10/22/2024Buy Now109.74%RBC Capital
Brian Abrahams49%
$1260 → $1260ReiteratesOutperform → OutperformGet Alert
10/16/2024Buy Now89.26%Truist Securities
Srikripa Devarakonda45%
$1200 → $1137MaintainsBuyGet Alert
10/04/2024Buy Now109.74%RBC Capital
Brian Abrahams49%
$1252 → $1260MaintainsOutperformGet Alert
09/24/2024Buy Now108.41%RBC Capital
Brian Abrahams49%
$1282 → $1252MaintainsOutperformGet Alert
09/24/2024Buy Now116.4%BMO Capital
Evan David Seigerman47%
$1300 → $1300ReiteratesOutperform → OutperformGet Alert
09/24/2024Buy Now99.75%Truist Securities
Srikripa Devarakonda45%
$1200 → $1200ReiteratesBuy → BuyGet Alert
09/24/2024Buy Now79.28%Leerink Partners
David Risinger70%
$1175 → $1077DowngradeOutperform → Market PerformGet Alert
09/23/2024Buy Now99.75%Wells Fargo
Mohit Bansal68%
$1200 → $1200ReiteratesOverweight → OverweightGet Alert
09/17/2024Buy Now113.4%RBC Capital
Brian Abrahams49%
$1282 → $1282ReiteratesOutperform → OutperformGet Alert
09/16/2024Buy Now68.96%Cantor Fitzgerald
Olivia Brayer54%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
09/09/2024Buy Now68.96%Cantor Fitzgerald
Olivia Brayer54%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
09/09/2024Buy Now113.4%RBC Capital
Brian Abrahams49%
$1250 → $1282MaintainsOutperformGet Alert
09/05/2024Buy Now108.07%RBC Capital
Brian Abrahams49%
$1250 → $1250ReiteratesOutperform → OutperformGet Alert
08/23/2024Buy Now106.74%Piper Sandler
Christopher Raymond56%
$1166 → $1242MaintainsOverweightGet Alert
08/02/2024Buy Now99.75%JP Morgan
Chris Schott40%
$1150 → $1200MaintainsOverweightGet Alert
08/02/2024Buy Now106.41%RBC Capital
Brian Abrahams49%
$1232 → $1240MaintainsOutperformGet Alert
08/02/2024Buy Now116.4%Guggenheim
Yatin Suneja58%
$1180 → $1300MaintainsBuyGet Alert
08/02/2024Buy Now99.75%Wells Fargo
Mohit Bansal68%
$1125 → $1200MaintainsOverweightGet Alert
08/02/2024Buy Now103.08%Barclays
Carter Gould57%
$1200 → $1220MaintainsOverweightGet Alert
08/02/2024Buy Now99.75%Truist Securities
Srikripa Devarakonda45%
$1135 → $1200ReiteratesBuy → BuyGet Alert
07/23/2024Buy Now99.75%TD Cowen
Tyler Van Buren45%
$1030 → $1200MaintainsBuyGet Alert
07/22/2024Buy Now66.46%Cantor Fitzgerald
Olivia Brayer54%
$925 → $1000MaintainsNeutralGet Alert
07/19/2024Buy Now94.09%Piper Sandler
Christopher Raymond56%
$1000 → $1166MaintainsOverweightGet Alert
07/18/2024Buy Now96.42%Guggenheim
Yatin Suneja58%
$1040 → $1180MaintainsBuyGet Alert
07/11/2024Buy Now96.76%Morgan Stanley
Matthew Harrison61%
$1183 → $1182MaintainsOverweightGet Alert
07/10/2024Buy Now99.75%Barclays
Carter Gould57%
$1050 → $1200MaintainsOverweightGet Alert
06/27/2024Buy Now91.76%Canaccord Genuity
John Newman45%
$1152 → $1152MaintainsBuyGet Alert
06/25/2024Buy Now94.76%Argus Research
Jasper Hellweg68%
$1060 → $1170MaintainsBuyGet Alert
06/24/2024Buy Now104.58%RBC Capital
Brian Abrahams49%
$1229 → $1229ReiteratesOutperform → OutperformGet Alert
06/17/2024Buy Now91.43%JP Morgan
Chris Schott40%
$1050 → $1150MaintainsOverweightGet Alert
06/12/2024Buy Now104.58%RBC Capital
Brian Abrahams49%
$1200 → $1229MaintainsOutperformGet Alert
06/04/2024Buy Now99.75%RBC Capital
Brian Abrahams49%
$1185 → $1200MaintainsOutperformGet Alert
05/14/2024Buy Now91.43%Evercore ISI Group
Cory Kasimov66%
→ $1150Initiates → OutperformGet Alert
05/03/2024Buy Now53.98%Cantor Fitzgerald
Olivia Brayer54%
$925 → $925ReiteratesNeutral → NeutralGet Alert
04/24/2024Buy Now71.45%TD Cowen
Tyler Van Buren45%
$1020 → $1030MaintainsBuyGet Alert
04/17/2024Buy Now82.94%UBS
Colin Bristow39%
$1090 → $1099MaintainsBuyGet Alert
04/17/2024Buy Now53.98%Cantor Fitzgerald
Olivia Brayer54%
→ $925ReiteratesNeutral → NeutralGet Alert
04/15/2024Buy Now53.98%Cantor Fitzgerald
Louise Chen54%
$925 → $925ReiteratesNeutral → NeutralGet Alert
04/12/2024Buy Now19.85%B of A Securities
Geoff Meacham67%
$710 → $720MaintainsUnderperformGet Alert
04/09/2024Buy Now97.92%RBC Capital
Brian Abrahams49%
$1189 → $1189ReiteratesOutperform → OutperformGet Alert
04/03/2024Buy Now88.93%Truist Securities
Robyn Karnauskas54%
$1135 → $1135MaintainsBuyGet Alert
03/26/2024Buy Now88.93%Truist Securities
Robyn Karnauskas54%
$1135 → $1135MaintainsBuyGet Alert
03/13/2024Buy Now85.6%Morgan Stanley
Matthew Harrison61%
$1104 → $1115MaintainsOverweightGet Alert
03/12/2024Buy Now87.27%Bernstein
William Pickering39%
→ $1125Initiates → OutperformGet Alert
03/11/2024Buy Now87.27%Bernstein
Aaron Gal28%
→ $1125Initiates → OutperformGet Alert
02/27/2024Buy Now97.09%RBC Capital
Brian Abrahams49%
$1096 → $1184MaintainsOutperformGet Alert
02/06/2024Buy Now53.98%Cantor Fitzgerald
Olivia Brayer54%
$850 → $925MaintainsNeutralGet Alert
02/05/2024Buy Now84.77%RBC Capital
Brian Abrahams49%
$1076 → $1110MaintainsOutperformGet Alert
02/05/2024Buy Now80.11%BMO Capital
Evan David Seigerman47%
$1055 → $1082MaintainsOutperformGet Alert
01/29/2024Buy Now79.11%RBC Capital
Brian Abrahams49%
$1076 → $1076ReiteratesOutperform → OutperformGet Alert
01/23/2024Buy Now69.79%Barclays
Carter Gould57%
$935 → $1020MaintainsOverweightGet Alert
01/12/2024Buy Now79.11%RBC Capital
Brian Abrahams49%
→ $1076UpgradeSector Perform → OutperformGet Alert
01/09/2024Buy Now41.49%Cantor Fitzgerald
Olivia Brayer54%
$850 → $850ReiteratesNeutral → NeutralGet Alert
12/18/2023Buy Now73.95%Truist Securities
Robyn Karnauskas54%
→ $1045ReiteratesBuy → BuyGet Alert

FAQ

Q

What is the target price for Regeneron Pharmaceuticals (REGN) stock?

A

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by RBC Capital on May 27, 2025. The analyst firm set a price target for $943.00 expecting REGN to rise to within 12 months (a possible 56.97% upside). 78 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?

A

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by RBC Capital, and Regeneron Pharmaceuticals reiterated their outperform rating.

Q

When was the last upgrade for Regeneron Pharmaceuticals (REGN)?

A

The last upgrade for Regeneron Pharmaceuticals Inc happened on May 14, 2025 when Citigroup raised their price target to $700. Citigroup previously had a neutral for Regeneron Pharmaceuticals Inc.

Q

When was the last downgrade for Regeneron Pharmaceuticals (REGN)?

A

The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.

Q

Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?

A

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a reiterated with a price target of $943.00 to $943.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $600.75, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch